Evidence map›Paper›PMID 34588443›Full record

ArticleHuman genome variation2021

JCGA: the Japanese version of the Cancer Genome Atlas and its contribution to the interpretation of gene alterations detected in clinical cancer genome sequencing.

Masakuni Serizawa, Maki Mizuguchi, Kenichi Urakami, Takeshi Nagashima, Keiichi Ohshima, Keiichi Hatakeyama, Sumiko Ohnami, Shumpei Ohnami, Koji Maruyama, Tadashi Ashizawa and 6 more

Open access · goldAbstract read
In one paragraph

Article in Human genome variation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Masakuni SerizawaDrug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan. m.serizawa@scchr.jp.
Maki MizuguchiShizuoka Cancer Center, Shizuoka, Japan.
Kenichi UrakamiCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Takeshi NagashimaCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Keiichi OhshimaDrug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Keiichi HatakeyamaMedical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.ORCID http://orcid.org/0000-0001-6000-5899
Sumiko OhnamiCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Shumpei OhnamiCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Koji MaruyamaExperimental Animal Facility, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Tadashi AshizawaImmunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Akira IizukaImmunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Yasue HoriuchiCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Akane NaruokaDrug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.ORCID http://orcid.org/0000-0002-6401-0318
Hirotsugu KenmotsuDivision of Thoracic Oncology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Yasuto AkiyamaImmunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Ken YamaguchiShizuoka Cancer Center, Shizuoka, Japan.
Shizuoka Cancer Center · JP

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) 19K07792
6 · The paper itself

Abstract

With the emergence of next-generation sequencing (NGS)-based cancer gene panel tests in routine oncological practice in Japan, an easily interpretable cancer genome database of Japanese patients in which mutational profiles are unaffected by racial differences is needed to improve the interpretation of the detected gene alterations. Considering this, we constructed the first Japanese cancer genome database, called the Japanese version of the Cancer Genome Atlas (JCGA), which includes multiple tumor types. The database includes whole-exome sequencing data from 4907 surgically resected primary tumor samples obtained from 4753 Japanese patients with cancer and graphically provides genome information on 460 cancer-associated genes, including the 336 genes that are included in two NGS-based cancer gene panel tests approved by the Pharmaceuticals and Medical Devices Agency. Moreover, most of the contents of this database are written in Japanese; this not only helps physicians explain the results of NGS-based cancer gene panel tests but also enables patients and their families to obtain further information regarding the detected gene alterations.

Identifiers

PMID34588443
PMCPMC8481308
OpenAlexW3204108824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.